Evidence map›Paper›PMID 26743470›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2016

The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation.

Masashi Kato, Toyonori Tsuzuki, Kyosuke Kimura, Akihiro Hirakawa, Fumie Kinoshita, Naoto Sassa, Ryo Ishida, Akitoshi Fukatsu, Tohru Kimura, Yasuhito Funahashi and 3 more

Open access · bronzeAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Observational
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Masashi KatoDepartment of Urology, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Toyonori TsuzukiDepartment of Pathology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan.
Kyosuke KimuraDepartment of Urology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Akihiro HirakawaCenter for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
Fumie KinoshitaCenter for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
Naoto SassaDepartment of Urology, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Ryo IshidaDepartment of Urology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan.
Akitoshi FukatsuDepartment of Urology, Komaki City Hospital, Komaki, Japan.
Tohru KimuraDepartment of Urology, Chukyo Hospital, Nagoya, Japan.
Yasuhito FunahashiDepartment of Urology, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Yoshihisa MatsukawaDepartment of Urology, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Ryohei HattoriDepartment of Urology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan.
Momokazu GotohDepartment of Urology, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Nagoya University · JPJapanese Red Cross Nagoya Daini Hospital · JPNagoya University Hospital · JPChukyo Hospital · JPJapanese Red Cross Nagoya Daiichi Hospital · JPKomaki City Hospital · JPNagoya Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intraductal carcinoma of the prostate is an adverse prognostic factor in localized prostate cancer patients. However, whether it influences outcome of those patients with distant metastases discovered at initial diagnosis is unclear. Here, we evaluated whether the presence of intraductal carcinoma of the prostate in prostate needle biopsies is an adverse prognostic factor for cancer-specific survival and overall survival in such prostate cancer patients. We retrospectively enrolled 150 eligible patients. All patients received androgen-deprivation therapy and/or chemotherapy. Their age, performance status, pain, metastatic sites, clinical T stage, serum prostate-specific antigen, alkaline phosphatase, hemoglobin, Gleason score, and the presence of Gleason pattern 5 were analyzed. Primary end point was cancer-specific survival; secondary end points included prostate-specific antigen progression-free survival and overall survival. Fine and Gray's model and the Cox proportional hazards model were used as statistical tests. Intraductal carcinoma of the prostate was detected in 100 (67%) patients. At a median follow-up of 38 months, 79 patients (53%) had died of the disease and nine (6%) had died of other causes. The average time interval to cancer-related death was 28 months. On multivariate analysis, only intraductal carcinoma of the prostate was significantly associated with cancer-specific survival (P=0.018) and overall survival (P=0.001), and only the presence of Gleason pattern 5 was significantly associated with prostate-specific antigen progression-free survival (P=0.026). The presence of intraductal carcinoma of the prostate was the only significant prognostic parameter for cancer-specific survival and overall survival in prostate cancer patients with distant metastasis at presentation. These results may prove useful in planning future treatments.

Indexed as

Biopsy, NeedleAgedAged, 80 and overAndrogen AntagonistsAntineoplastic Agents, HormonalCarcinoma, Pancreatic DuctalDisease-Free SurvivalHumansJapanKaplan-Meier EstimateMaleMiddle AgedNeoplasm GradingPredictive Value of TestsProportional Hazards ModelsProstatic NeoplasmsAndrogen AntagonistsAntineoplastic Agents, Hormonal

Identifiers

PMID26743470
OpenAlexW2229746266

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.